Product · #4 of 27 · peri/menopause

Thorne Perimenopause Complete

Capsule from Thorne, made by Thorne Research. Daily serving: 2 capsules.

Last updated · Price and ratings checked Nov 19, 2026

In short: Thorne Perimenopause Complete scores 64.6/100 in our ranking (#4 of 27). It costs $1.73 a day at the regular price. Evidence: EstroG-100 514 mg (trial dose) + hops; best ingredient grade C (EstroG-100). It is listed in NSF’s public registry.

Pros

  • Listed in NSF's public registry (NSF/ANSI 173 contents certification, NSF Certified for Sport).
  • Evidence: EstroG-100 514 mg (trial dose) + hops.

Cons

  • Expensive: $1.73 a day at the label dose.
  • Few Amazon ratings so far (72).

Flags

Liver cautionAbove EFSA limit

Score breakdown

Evidence
25/40
NSF-verified testing
20/20
Value ($/day)
9.6/20
Ingredients
6/10
Amazon rating
4/10

How we score

Full label: what's in it

Supplement Facts actives per daily serving (2 capsules). Source: label or official page, checked Nov 19, 2026.
Ingredient (as labeled)Per dayEvidence page
EstroG-100 botanical blend514 mgEstroG-100 C
Hops extract (Lifenol, flower)85 mgHops (8-PN) C-
Vitamin B6 (pyridoxal 5'-phosphate)30 mgNot in our evidence library

Replaces Thorne Meta-Balance, which is discontinued.

Evidence

Our evidence score: 25/40, because: EstroG-100 514 mg (trial dose) + hops.

Product-level research: we found no published trial of this exact product, so its evidence comes from studies of its ingredients.

Ingredient evidence

  • EstroG-100 C (514 mg here)
    EstroG-100 is a Korean three-herb blend studied for occasional hot flashes and other common menopause symptoms* in three small placebo-controlled trials. The EU food-safety authority (EFSA) judged it safe only up to 175 mg a day, below the 514 mg a day used in most products. The Menopause Society 2023: Not specifically assessed (falls under 'supplements/herbal remedies – not recommended').
  • Hops (8-PN) C- (85 mg here)
    Hop extract, a source of the potent plant estrogen 8-prenylnaringenin (8-PN), has been studied in a few small trials for occasional hot flashes*, with mixed results. The Menopause Society 2023: Not assessed.

Studies

Studies on its ingredients (7)
  • The effect of herbal extract (EstroG-100) on pre-, peri- and post-menopausal women: a randomized double-blind, placebo-controlled study.

    Chang A, Kwak BY, Yi K et al. · Phytother Res 2012 · EstroG-100

    64 US women took EstroG-100 (a Korean 3-herb blend) or placebo for 12 weeks. Overall symptom scores, including hot flashes and vaginal dryness, improved much more than with placebo. It is one small study and has not been widely repeated.

    Who
    64 women (US, multi-ethnic)
    Dose
    EstroG-100 daily
    Duration
    12 weeks
    Result
    Kupperman Index 29.5→11.3 vs 29.2→23.7 placebo (P<.01); vaginal dryness improved.
    Funding
    Not stated in abstract (ingredient maker Naturalendo Tech is the developer; not verified). Funding not stated

    PubMed · Full text (DOI)

  • Estro G-100 herbal extract and hot flashes in postmenopausal women: A randomized double-blinded controlled trial.

    Farzaneh F, Fallah G, Khalili-Chelik A et al. · Explore (NY) 2024 · EstroG-100

    In Iran, postmenopausal women took EstroG-100 or placebo; only 70 of 120 were analyzed. By week 6 the EstroG-100 group reported fewer hot flashes. The high drop-out rate weakens the result.

    Who
    120 randomized, 70 analyzed (Iran)
    Dose
    EstroG-100 daily
    Duration
    12 weeks (results reported at weeks 3–6)
    Result
    Fewer mild, moderate and severe hot flashes vs control at week 6 (P<.001).
    Funding
    Not stated in abstract. Funding not stated

    PubMed · Full text (DOI)

  • Effect of a novel nutraceutical combination of EstroG-100 and γ-aminobutyric acid (GABA) in attenuating symptoms of menopause in healthy adult women: a randomized double-blinded placebo-controlled study.

    Snigdha S, Lau E, Ademola J et al. · Menopause 2025 · EstroG-100

    80 women took OLLY's EstroG-100 + GABA product or placebo for 5 weeks. Hot flashes, sleep and mood improved more than placebo. The study was run by the company that sells the product.

    Who
    80 women
    Dose
    EstroG-100 514 mg + GABA 50 mg (OLLY Mellow Menopause)
    Duration
    5 weeks
    Result
    Hot-flash intensity and number fell vs placebo from days 1–2; sleep, mood and sexual function improved at later time points.
    Funding
    Authors are employees of OLLY PBC, the product's manufacturer. Industry-linked

    PubMed · Full text (DOI)

  • Statement on the safety of EstroG-100™ as a novel food pursuant to Regulation (EC) No 258/97.

    EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), Turck D, Bresson JL et al. · EFSA J 2017 · EstroG-100

    Europe's food-safety agency approved EstroG-100 only up to 175 mg a day – about a third of the dose used in many US products and trials – because of limited long-term safety data.

    Who
    n/a (EU safety opinion)
    Dose
    max 175 mg/day judged safe
    Duration
    n/a
    Result
    EFSA considered EstroG-100 safe at 175 mg/day in postmenopausal women (lower than the 514 mg/day proposed) because of liver/blood findings in animal studies and limited human data.
    Funding
    EFSA (independent EU regulator). Independent / academic

    PubMed · Full text (DOI)

  • A first prospective, randomized, double-blind, placebo-controlled study on the use of a standardized hop extract to alleviate menopausal discomforts.

    Heyerick A, Vervarcke S, Depypere H et al. · Maturitas 2006 · Hops (8-PN)

    67 Belgian women took a hop extract or placebo for 12 weeks. There was an early benefit at 6 weeks that was no longer significant at 12 weeks.

    Who
    67 women
    Dose
    hop extract 100 or 250 µg 8-PN/day
    Duration
    12 weeks
    Result
    100 µg beat placebo at 6 weeks but not 12 weeks; no dose-response.
    Funding
    Not stated in abstract. Funding not stated

    PubMed · Full text (DOI)

  • A randomized, double-blind, placebo-controlled, cross-over pilot study on the use of a standardized hop extract to alleviate menopausal discomforts.

    Erkkola R, Vervarcke S, Vansteelandt S et al. · Phytomedicine 2010 · Hops (8-PN)

    36 Finnish women took a hop extract and placebo for 8 weeks each. Overall it did not beat placebo.

    Who
    36 women (crossover)
    Dose
    standardized hop extract
    Duration
    16 weeks (8+8)
    Result
    No significant overall effect; some time-specific improvements.
    Funding
    Not stated in abstract. Funding not stated

    PubMed · Full text (DOI)

  • The effect of Hop (Humulus lupulus L.) on early menopausal symptoms and hot flashes: A randomized placebo-controlled trial.

    Aghamiri V, Mirghafourvand M, Mohammad-Alizadeh-Charandabi S et al. · Complement Ther Clin Pract 2016 · Hops (8-PN)

    120 Iranian women took hops or placebo for 12 weeks and reported fewer hot flashes with hops. One unreplicated study.

    Who
    120 women (Iran)
    Dose
    hop tablets
    Duration
    12 weeks
    Result
    Greene score and hot-flash counts lower vs placebo at weeks 4, 8, 12.
    Funding
    Academic (Tabriz Univ.). Independent / academic

    PubMed · Full text (DOI)

The Menopause Society's 2023 statement is in the study library.

Price

Regular one-time price$52.00 (60 units, 30 days at label dose)
Cost per day$1.73
Subscription$46.80 (10% off)
Price notesAmazon B0GMYXQJTN $52.00
In stock when checkedYes
CheckedNov 19, 2026

Ratings

Amazon: no average shown from 72 ratings on Amazon (checked Nov 19, 2026)

Brand site: ★ 3.5, 25 reviews on thorne.com (checked Nov 19, 2026). Brand-site reviews are moderated by the brand.

Star ratings reflect buyer satisfaction, not clinical effect.

Certifications and claims

Verified in a public registry

  • NSF/ANSI 173 Contents Certified – 'Thorne® Perimenopause Complete' (info.nsf.org Thorne listing, 2026-11-19) Registry-verified
  • NSF Certified for Sport – listed in nsfsport.com search 'perimenopause' (2026-11-19) Registry-verified

Claims made by the brand

  • “gluten-free” Brand claim
  • “dairy-free” Brand claim
  • “soy-free” Brand claim

Registry check: info.nsf.org · nsfsport.com

Who's behind it

BrandThorne
Owner / companyThorne Research (Summerville, SC). Reported to have been taken private by L Catterton in 2023. Unverified
FoundersNot stated on the pages we read.
Where it's madeNot stated on the pages we read.
Medical advisors namedNone named on the pages we read.
Sourcethorne.com

Flags & safety

Legal, regulatory and quality flags

  • Thorne Meta-Balance (black cohosh 200 mg, chaste tree 200 mg, wild yam 200 mg, Pycnogenol 60 mg) is discontinued: thorne.com URL 404 and no Amazon listing (2026-11-19). Many review sites still recommend it.
  • Contains EstroG-100 at 514 mg/day. EFSA judged EstroG-100 safe only up to 175 mg/day in postmenopausal women, because of liver and blood findings in animal studies. study

Ingredient safety notes

  • EstroG-100: EFSA: safe only up to 175 mg/day in postmenopausal women (vs 514 mg/day used in many products) due to liver/haematology findings in animals and limited human data. Angelica species may interact with anticoagulants (dong quai concern noted by NAMS).
  • Hops (8-PN): 8-PN is a potent phytoestrogen – caution in hormone-sensitive conditions.

Not verified

  • Ownership (reported L Catterton take-private, 2023). Unverified

Sources

Talk to a clinician first

The Menopause Society's 2023 nonhormone position statement does not recommend any dietary supplement or herbal remedy for hot flashes, because the research is limited or mixed. Hormone therapy is an option for many women, and the statement lists non-hormonal options with evidence behind them: CBT, clinical hypnosis, SSRIs/SNRIs, gabapentin, fezolinetant (Level I), oxybutynin (I–II), weight loss, stellate ganglion block (II–III).

If hot flashes, night sweats, sleep or mood are affecting your life, talk to a clinician first. If you still want to try a supplement, the rankings below show what is actually in each one, what the research found, and who is behind it. Sources: position statement (PDF) · PubMed.

*These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease. Solynes does not sell supplements; descriptions summarize published research and are not medical advice.